In Brief
Genentech appealed against a High Court order that reversed an interim direction preventing the Drug Controller from allowing Reliance's biosimilar Trastuzumab in government procurement. The Supreme Court held that the High Court order wrongly unsettled the three-and-a-half-year status quo without analogously considering Genentech's applications and without awaiting the pending intellectual property suit's conclusion. The Court restored the interim direction while noting this expression had no bearing on the High Court proceedings, requesting expedited disposal within 12 months.
The lawyer headnote and full judgment text are available to registered users.